CV Therapeutics have announced results that show ranolazine significantly shortens the QT interval of patients with a hereditary form of long QT syndrome called LQT3. Ranolazine also shortened cardiac relaxation time in the study.
Filed under: Uncategorized | Tagged: antagonist, CV therapeutics, na channel, Sodium channel | Leave a Comment »
CV Therapeutics have announced that the FDA is continuing its review of Ranexa (ranolazine extended-release tablets) even though the PDUFA action date of July 27, 2008 has been met. The drug is under review for first line treatment of chronic angina and a significant reduction in cautionary language, based on substantial data from the MERLIN [...]
Filed under: Sodium channel | Tagged: antagonist, CV therapeutics, na channel, Regulatory, Sodium channel | Leave a Comment »
CV Therapeutics have announced that the EMEA has granted approval for ranolazine in the treatment of patients with chronic angina in all 27 European Union (EU) member states.
Filed under: Uncategorized | Tagged: antagonist, CV therapeutics, CVT-303, CVT303, na channel, Ranolazine, Sodium channel | Leave a Comment »
